N-acetyl-L-cysteine

Phase 2Small molecule

PPeking University People's Hospital

N-acetyl-L-cysteine is one of 77 small molecule programs targeting Acute Liver Failure. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Liver FailureActive, not recruiting

HSCTNot yet recruiting

RecoveryNot yet recruiting

Acute Myeloid LeukemiaActive, not recruiting

Acute Liver FailurePreclinical

Active, not recruiting

HSCTPhase 2

Not yet recruiting

RecoveryPhase 2

Not yet recruiting

Acute Myeloid LeukemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

255 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

59 2

Xospata

Astellas

Phase 3

24 3

Fludara

Sanofi

Phase 3

17 4

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

42 5

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 6

Vanflyta

Daiichi Sankyo

Phase 3

14 7

Neupogen

EEastern Cooperative Oncology Group

Phase 3

31 8

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

30 9

Nexavar

Cellcept

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Liver Failure1 trial

High-Volume Plasma Exchange Versus Standard Medical Treatment in Patients With Acute Liver Failure

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02718079·40 enrolled

Neuropathic Pain1 trial

The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain

Completed·VVirginia Commonwealth University·Phase 2·NCT01840345·11 enrolled

Thrombocytopenia1 trial

Prolonged Isolated Thrombocytopenia After Allo-SCT : N-acetyl-L-cysteine (NAC) Versus Supportive Therapy

Terminated·PPeking University People's Hospital·Phase 2/3·NCT03391856·15 enrolled

Hematopoietic Stem Cell Transplantation1 trial

Effect of NAC on the Hematopoietic Reconstitution After Haploidentical Hematopoietic Stem Cell Transplantation

Completed·PPeking University People's Hospital·Phase 2·NCT03236220·35 enrolled

HSCT1 trial

AZA Combined With NAC for PIT After HSCT

Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT05126004·100 enrolled

4 more indications

Risk Stratification1 trial

Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution

Unknown status·PPeking University People's Hospital·Phase 3·NCT03967665·130 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Adding Intravenous N-acetyl Cysteine in Colon Surgeries

Completed·—·Phase 4·NCT03589495·60 enrolled

Recovery1 trial

NAC for Hematopoietic Recovery in SAA

Not yet recruiting·PPeking University People's Hospital·Phase 2·NCT06518044·30 enrolled

Acute Myeloid Leukemia1 trial

NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After Chemotherapy

Active, not recruiting·PPeking University People's Hospital·Phase 2·NCT06024031·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for N-acetyl-L-cysteine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — N-acetyl-L-cysteine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for N-acetyl-L-cysteine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPeking University People's Hospital

N-acetyl-L-cysteine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Liver Failure1 trial

Neuropathic Pain1 trial

Thrombocytopenia1 trial

Hematopoietic Stem Cell Transplantation1 trial

HSCT1 trial

Risk Stratification1 trial

Safety and Efficacy1 trial

Recovery1 trial

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News